PubMed Health⌕ Search

Biomedical subjects

W Cendrowski

Publications and source records attributed to W Cendrowski.

At least 19 recordsLinked to original sources
PubMed1991

[Diagnosis and etiopathogenesis of retinitis in patients with multiple sclerosis].

Presented are: the incidence, symptomatology and diagnostics together with electroretinography of retinal periphlebitis as well as retinitis and maculopathy in patients with multiple sclerosis. Particular attention is called to the histopathology of the retina in this disease. The etiopathology of retinitis and maculopathy in multiple sclerosis is still unknown. Four etiopathological hypotheses are shortly discussed.

Electroretinography↗
PubMed1990

Temporary chromatopsia and alternate umbropsia in multiple sclerosis.

Uncommon visual symptoms were described in two women with clinically definite, remittent multiple sclerosis. In the first case with right optic atrophy temporary chromatopsia (vision of only blue colour) and left-sided, paroxysmal and alternate "fading out" followed by "brightening up" vision (umbropsia) occurred spontaneously. In the second case with bilateral optic atrophy transient chromatopsia (vision of only green colour) and short-lived "fading out" vision when fixating on a target were noted. Chromatopsia might be associated with impaired function of selected optic nerve fibers conducting impulses from a limited population of retinal ganglion cells. Alternate umbropsia and short-lived "fading out" vision probably depend on paroxysmal, frequency-related intermittent conduction block at the level of optic nerve fibers or synaptic elements.

Adolescent↗
PubMed1979

Antilymphocyte globulin and adrenal steroids in the treatment of multiple sclerosis: short report based on seven cases.

A therapeutic trial of antilymphocyte globulin (ALG) combined with dexamethasone was carried out in 7 patients with chronic, relapsing multiple sclerosis. ALG was given intravenously in daily doses of 0.25-0.5 g on the weekdays over 1 to 2 months. Total doses of ALG ranged from 12.5 to 17.7 g. Follow-up made after 1 year showed that 2 had no deterioration and 2 became worse in "tolerant" group, and 2 showed no deterioration and 1 revealed fatal progression in "non-tolerant" group. The treatment proved to be toxic in 3 patients. This pilot study suggests that ALG enhances anti-inflammatory activity of adrenal steroids in some patients, but does not seem to change natural course of the disease.

Adult↗
PubMed1978

Levamisole in multiple sclerosis; with special reference to immunological parameters. A pilot study.

Nineteen patients with multiple sclerosis (MS) have been given one course of levamisole therapy, and 16 patients two courses of levamisole treatment in daily dosages of 100--150 mg over two periods lasting from 1 month to 22 weeks each. Clinical effect was evaluated using Kurtzke's disability status scale. Immediate clinical evaluation showed that 15 patints remained unchanged, two improved and two became worse. Follow-up revealed after 4--14 months that another four patients deteriorated and none improved. Altogether 10 patients developed 13 relapses. During this brief therapy, no convincing conclusions may be drawn regarding an influence upon the course of the disease, although there is the suggestion that levamisole was not beneficial in MS patients. There was no statistically significant effect of levamisole on peripheral blood lymphocyte count, lymphocyte stimulation tests, leucocyte migration inhibition tests, short and long incubation E-rosette forming cells and serum IgA, IgG or IgM levels. A group of MS patients showed after 1 month of levamisole treatment either short-lasting restored or potentiated skin hypersensitivity to bacterial and fungal antigens (P less than 0.05).

Administration, Oral↗
PubMed1978

[Haptoglobin levels in the serum and the cerebrospinal fluid patients with multiple sclerosis].

In 47 patients with multiple sclerosis and 10 with other diseases of the nervous system determinations of haptoglobin were performed in the serum and cerebrospinal fluid by the method of Owen et al. The Hp level in the serum of multiple sclerosis patients was normal. Its level in the cerebrospinal fluid was higher in multiple sclerosis patients than in cases of other nervous system diseases (statistically significant difference, p less than 0.001). Raised value of the Hp/IgG index in the cerebrospinal fluid of multiple sclerosis patients points to increased permeability of the blood-brain barrier. The so called normal Hp/IgG index was found in multiple sclerosis patients with high Hp and IgG level. Low Hp/IgG index suggested the possibility of IgG synthesis in the brain of patients with this disease. The comparison of the protein level and protein indexes showed that raised IgG level in the cerebrospinal fluid was present in 80% of multiple sclerosis cases, raised Kabat index in 50%, and low Hp/IgG index in 48%.

Haptoglobins↗
PubMed1977

Serological studies on the etiological role of measles-like virus in subacute sclerosing panencephalitis.

Significantly higher CSF titers of hemagglutination (HI) measles virus antibody were found in 22 patients with subacute sclerosing panencephalitis (SSPE) and more elevated titers of measles virus neutralization (NV) antibody were encountered in 19 patients with SSPE than in 50 children and young adults with other neurological diseases. Similar differences occurred in the sera of patients and controls. The serum: CSF antibody ratio was examined in 15 SSPE cases. All but one patient showed reduced antibody ratio (less than 80) as compared with the normal index. In addition, serological studies in some SSPE patients showed the presence of CSF antimeasles fluorescent (FA) and mixed hemadsorption (HAd) antibodies as well as serum anti-ribonucleoprotein antibody (RNP), HAd and FA had titers from 1:16 to 1:32000. SSPE patients harbored serum antibodies against three components of the measles virus as measles patients did. Most of SSPE patients had increasing CSF and serum titers of measles-like virus antibodies over the course of the disease.

Adolescent↗
PubMed1977

Clonazepam, baclofen and placebo in the treatment of spasticity.

25 patients with multiple sclerosis (MS) and other spastic disorders, 33 MS patients and 10 control patients with MS were given clonazepam, baclofen or placebo over a period of 5 days to 20 weeks. Both clonazepam and baclofen were significantly more effective than placebo in the treatment of spasticity (p less than 0.005 or p less than 0.01). A clinical trial of clonazepam versus baclofen was carried out and this showed no significant difference between the two drugs. However, there was indication that clonazepam influenced with better improvement in patients with slight muscle hypertonia mainly of cerebral origin. Patients with more severe forms, mainly of spinal spasticity, benefited rather from baclofen treatment (Fisher's test, p = 0.003). There was suggestion that combination of the two drugs may be more effective in some patients than than clonazepam or baclofen alone.

Adolescent↗
PubMed1976

Measles virus infection and multiple sclerosis: serological studies.

In 159 patients out of 161 with multiple sclerosis (MS), a significant rise in the level of measles hemagglutination inhibition (HI) antibody was found in the serum and in 92 MS patients the occurrence of measles HI antibody in the CSF was significantly more frequent. MS patients showed CSF humoral response against measles virus by neutralizing test (NV) (76%) more often than by hemagglutination test (37%). CSF FA antibody was found in 60%. In the serum of MS patients the presence of NV, HAd, FA, and GP-RNP was observed. 87% of MS patients showed lowered serum: CSF NV or HI antibody ratios and 78% had a diminished FA antibody ratio. Longitudinal study of serum HI measles virus antibody showed no substantial changes over longer period of the disease. Higher CSF measles antibody titer was found in more disabled patients with a malignant course of the disease (P less than 0.001). It is concluded that either persistent infection with proviruses or nonspecific stimulation of certain clones in individuals with genetic susceptibility provides for an excessive synthesis of humoral viral antibodies in MS.

Adolescent↗
PubMed1976

Penicillamine in multiple sclerosis. Therapeutic trial and design of uncontrolled pilot drug study.

Twenty-three patients with the chronic progressive or intermittent relapsing form of multiple sclerosis (MS) were treated with d-penicillamine over a period from 6 weeks to 12 months. Clinical effect was evaluated using Kurtzke's disability status scale with follow-up lasting from 7 weeks to 15 months. Fifteen patients remained unchanged, 7 became worse and 1 improved after the treatment. Administration of penicillamine to patients with MS resulted in an insignificant lowering of serum IgA, IgG and IgM levels. It is concluded that penicillamine neither prevented the occurrence of relapses nor slowed down the chronic progressive course of multiple sclerosis.

Adult↗
PubMed1976

Multiple sclerosis and childhood infections.

There is evidence that some event in childhood may determine risk of multiple sclerosis: Elevated titers to measles and other childhood infections suggest a childhood infection. Therefore, childhood infections reported by 30 patients with multiple sclerosis and matched controls were compared. Patients reported a childhood infection between 5 and 9 years (not simply exposure to an infection) more often than controls. The mean age of measles peaked somewhat later (age 7) in patients than in controls (age 4); this differnce approached statistical significance (p less than 0.1). Evidence that host response to measles is age-dependent was reviewed. It was proposed that age of measles (rather than the fact of injection) may influence the risk of developing multiple sclerosis.

Adolescent↗